Lou DH et al. investigated the role of ATO in ovarian cancer angiogenesis and found that ATO inhibits VEGFA and VEGFR2 expression, thereby inhibiting the VEGFA-VEGFR2-PI3K/ERK signaling pathway [44]. Here, KDR is linked to ovarian carcinoma.